Allen ? ? ? ? ? ? ? ?
Founder
OncoSynergy
OncoSynergy develops a first‑in‑class, de‑immunized pan‑CD29 monoclonal antibody (OS2966) for high‑grade gliomas, delivering it directly into the brain via convection‑enhanced delivery using a multi‑port catheter. This approach bypasses the blood‑brain barrier to achieve therapeutic concentrations at the tumor site, aiming to improve safety and efficacy for patients with recurrent glioblastoma and other solid or hematologic cancers.
- Biotechnology
Updated 5 months ago
Funding
Raised to date
$3.3MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Problem
High-grade gliomas such as recurrent glioblastoma are difficult to treat because the blood‑brain barrier (BBB) prevents many systemic cancer therapies from reaching tumor tissue, leading to limited efficacy and poor patient outcomes.
Solution
OncoSynergy is developing OS2966, a humanized, de‑immunized pan‑CD29 monoclonal antibody that blocks a cell‑surface receptor essential for tumor growth, invasion, and treatment resistance. To bypass the BBB, the drug is administered directly into the brain using convection‑enhanced delivery (CED) via the Infuseon Cleveland Multiport Catheter, allowing precise, localized infusion into the tumor and infiltrated brain tissue. The Phase 1 trial evaluates safety and tolerability in adult patients undergoing surgical resection of recurrent high‑grade glioma. By delivering a targeted antibody directly to the disease site, OncoSynergy aims to achieve therapeutic concentrations unattainable with conventional systemic administration, potentially improving response rates in a patient population with few effective options.
Target Audience
Primary customers are academic medical centers and oncology hospitals conducting neurosurgical oncology trials, as well as pharmaceutical partners seeking to co‑develop or license direct‑delivery immunotherapy platforms for brain tumors.
Features
- First‑in‑class, de‑immunized pan‑CD29 monoclonal antibody designed to inhibit tumor proliferation and resistance mechanisms
- Convection‑enhanced delivery (CED) technique enables direct, controlled infusion of the antibody into brain tumor tissue
- Use of the Infuseon Cleveland Multiport Catheter for multi‑port, homogeneous distribution of therapy within the tumor and surrounding infiltrated brain
- Clinical‑stage development with a Phase 1 trial focused on safety, tolerability, and pharmacokinetics in recurrent/progressive high‑grade glioma patients
- Additional pipeline candidates include a heat‑shock protein modulator for solid tumors and approaches for drug‑resistant acute lymphoblastic leukemia